Allergan tells Federal Circuit Restasis patents are valid

11-01-2018

Allergan tells Federal Circuit Restasis patents are valid

Mark_Kuiken / iStockphoto.com

Allergan and the Native American tribe that acquired Allergan’s patents for Restasis (cyclosporine ophthalmic emulsion) have told the US Court of Appeals for the Federal Circuit that patents covering the dry eye treatment are valid.


generics, Restasis, patent invalidation, Allergan, Saint Regis Mohawk Tribe, sovereign immunity, US Court of Appeals for the Federal Circuit

LSIPR